GLENMARK PHARMA : USA LAUNCHES OLANZAPINE FOR INJECTION, 10 MG/VIAL, SINGLE-DOSE VIAL

• Glenmark Pharmaceuticals Inc., USA has launched Olanzapine for Injection, 10 mg/vial, Single-Dose Vial. • The product is bioequivalent and therapeutically equivalent to Zyprexa® IntraMuscular Injection 10 mg/vial. • According to IQVIA® sales data, the Zyprexa® IntraMuscular Injection market achieved annual sales of approximately $25.4 million for the 12-month period ending May 2026. • The launch underscores the company's strategic focus on growing its injectables portfolio and strengthening its presence within the institutional channel.

Glenmark Pharmaceuticals Limited

Open attachment

← Back to feed